| Budget Amount *help |
¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2012: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2011: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2010: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2009: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Research Abstract |
The aim of this study was to clarify unknown mechanisms relating to angiogenesis in graft acceptance and tissue regeneration. Moreover, we aimed to develop novel therapeutic strategy inducing durable immunoregulation and long-term acceptance in organ and cell transplantation. We found that TWEAK/Fn14 pathway plays a critical role in ischemia-reperfusion injury. Importantly, Fn14 blockade had a significant inhibitory effect on inhibition of injury. In inflammatory bowel disease model, we うい erythropoietin, which has a proangiogenic property, was found to not only prevent tissue injury, but also accelerate tissue repair. These revealed mechanisms may lead to develop novel therapeutic strategy for intractable disease conditions.
|
